DCTH
Delcath Systems, Inc.
DCTH's outlook is improving, though it still trails on the overall score.
LLY
Eli Lilly and Company
LLY has the edge over DCTH overall, supported by stronger fundamentals and lower modeled downside.
DCTH Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
DCTH's revenue, profitability, cash flow and balance sheet are all currently healthy.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
DCTH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 117x | $18.66 | -13% |
| Current | 134x | $21.38 | — |
| Fair | 166x | $26.50 | +24% |
| Forward | 1,071x | $21.38 | — |
| Expensive | 1,435x | $230 | +974% |
Historical ranges are pointers, not guarantees.
DCTH has the edge over LLY in the historical PE scenario, which offers more potential upside but is not a forecast.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
DCTH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Returning to profit | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect DCTH to return to profit, with revenue growing.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
LLY has the edge over DCTH on the outlook, with more favorable valuation expectations.
DCTH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.02 | -88% |
| Q3 2026 | $0.16 | +167% |
| Q2 2026 | $0.01 | -90% |
| Q1 2026 | $0.01 | +$0.46 |
| Q4 2025 | $0.07 | +$1.00 |
| Q3 2025 | $0.06 | +$1.38 |
| Q2 2025 | $0.10 | +$2.62 |
| Q1 2025 | -$0.45 | +$2.17 |
| Q4 2024 | -$0.93 | +$2.01 |
DCTH earned $0.16 per share over the past year, up 167% from the year before.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over DCTH on earnings, with more consistent year-over-year improvement.
DCTH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $35.1M | +71% |
| Q2 2026 | $29.1M | +21% |
| Q1 2026 | $25M | +26% |
| Q4 2025 | $20.7M | +37% |
| Q3 2025 | $20.6M | +84% |
| Q2 2025 | $24.2M | +211% |
| Q1 2025 | $19.8M | +530% |
| Q4 2024 | $15.1M | +2701% |
DCTH has the edge over LLY on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 20% | +22 points |
| Q2 2026 | 8.2% | -2.5 points |
| Q1 2026 | -6.5% | -9.8 points |
| Q4 2025 | -11% | -31 points |
| Q3 2025 | -1.9% | +9.3 points |
| Q2 2025 | 11% | +61 points |
| Q1 2025 | 3.3% | +331 points |
| Q4 2024 | 20% | +2117 points |
DCTH's operating margin was 20% last quarter, up 22 points from the same quarter a year ago, near the top of its range since 2023.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY's revenue has grown year over year for 14 quarters in a row: $24.4B last quarter, up 39% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over DCTH on profitability, with a higher operating margin.
DCTH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $6.9M | +60% |
| Q2 2026 | $5.2M | -24% |
| Q1 2026 | $287K | -86% |
| Q4 2025 | $7.7M | +$8.9M |
| Q3 2025 | $4.3M | +$8.2M |
| Q2 2025 | $6.9M | +$11.4M |
| Q1 2025 | $2.1M | +$11.7M |
| Q4 2024 | -$1.2M | +$7M |
DCTH has burned cash in most quarters: $20M over the past year, up 67% from the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY generated $19.7B in free cash flow over the past year, up 112% from the year before.
DCTH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.2% | +1.3M shares |
| 1 year | +2.4% | +963K shares |
| 3 years | +229% | +28.6M shares |
| 5 years | +514% | +34.3M shares |
DCTH has 41M diluted shares, up 2.4% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | $11,000 |
| Q1 2026 | $3M |
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over DCTH on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
DCTH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -9.0x | Net Cash |
| Q4 2025 | -44.2x | Net Cash |
| Q3 2025 | -6.8x | Net Cash |
| Q2 2025 | -6.5x | Net Cash |
DCTH has the edge over LLY on leverage, with a lower net debt burden relative to earnings.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
DCTH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 76.6 | Overbought |
| Stochastic | 60.2 | Neutral |
DCTH's weekly RSI is 77 (overbought) and its Stochastic is 60 (neutral).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
DCTH PE vs Healthcare Sector
| Metric | DCTH | Sector median | Relative |
|---|---|---|---|
| PE | 134x | 26x | 417% above |
| PE % | 26 | 29 | 3 pts below |
DCTH is trading at 134x earnings, a 417% premium to the Healthcare sector's median of 26x.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY has the edge over DCTH on valuation relative to its sector.
DCTH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $15.6 | 37% above |
| 20 week MA | $15.1 | 41% above |
| 50 week MA | $12.2 | 75% above |
| 100 week MA | $12.3 | 73% above |
| 200 week MA | $9.19 | 133% above |
DCTH is in an uptrend: it's above all five of its weekly moving averages, and 133% above its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY is in an uptrend: it's above all five of its weekly moving averages, and 79% above its 200-week average.
DCTH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $24.0 | $17.1 | -29% |
| 2021 | $17.1 | $8.45 | -51% |
| 2022 | $8.45 | $3.59 | -58% |
| 2023 | $3.59 | $4.16 | +16% |
| 2024 | $4.16 | $12.0 | +188% |
| 2025 | $12.0 | $10.3 | -14% |
| 2026 YTD | $10.3 | $21.4 | +108% |
DCTH has the edge over LLY on returns for 2026, with the stronger performance.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has finished every year since 2020 higher, and it's up 32% so far in 2026.